Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter randomized phase III study of adjuvant treatment with epirubicin followed by docetaxel (E/T) versus epirubicin and docetaxel combination (ET) in high risk lymph node negative breast cancer patients.

Next Previous
Search
Trial Profile

A multicenter randomized phase III study of adjuvant treatment with epirubicin followed by docetaxel (E/T) versus epirubicin and docetaxel combination (ET) in high risk lymph node negative breast cancer patients.

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Docetaxel; Epirubicin
  • Indications Breast cancer
  • Focus Therapeutic Use

Most Recent Events

  • 20 May 2015 Biomarkers information updated
  • 04 Nov 2013 Planned end date changed from 1 Apr 2013 to 1 Apr 2014 as reported by ClinicalTrials.gov.
  • 12 Mar 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top